What to do after general resistance to Alpelisib-Piqray

Alpelisib (Alpelisib)-Piqray is a therapeutic drug for breast cancer that blocks the growth and spread of tumor cells by inhibiting the PI3K signaling pathway. Some patients may develop drug resistance after receiving apelvis treatment. Patients should inform their doctors in time, and molecular testing will be performed to determine the drug resistance mechanism. Doctors may consider adjusting the dose of Apelvis or switching to other treatment options, or trying to combine it with other anti-cancer drugs or targeted therapies to enhance the effectiveness of the treatment. If standard treatments are ineffective, patients may consider participating in relevant clinical trials. These trials may involve new drugs, treatment regimens or targeted treatment strategies to provide more treatment options for drug-resistant patients.